Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Reexamination Certificate
2000-04-21
2001-12-11
Dodson, Shelley A. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
C424S078070
Reexamination Certificate
active
06328984
ABSTRACT:
RELATED APPLICATIONS
This application claims from priority Japanese Patent Application No.11-115129 filed on Apr, 22, 1999 and Japanese Patent Application No.11-115130 filed on Apr. 22, 1999 which are incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates to a selective antibacterial composition and, in particular, to an improved antibacterial agent which is combined into an external preparation for application to the skin.
BACKGROUND OF THE INVENTION
In recent years, as the numbers of atopic dermatitis patients have increased, it has become known that the balance of the distribution of bacteria on the rough skin of an atopic dermatitis patient is disturbed. The harmless
Staphylococcus epidermidis
is the principal bacteria that always exists on the skin of healthy person. However, the harmful
Staphylococcus aureus
exists with
S.epidermidis
on the skin of the atopic dermatitis patient, such that the balance of the distribution of the bacteria on the skin deviates from the normal. It is also known that the symptom worsen with an increase of
S.aureus.
Therefore, conventionally, an external preparation for application to the skin for the treatment of atopic dermatitis contains an antibacterial agent to sterilize this harmful
S.aureus.
Usually, however, when the antibacterial agent is applied to the skin of the atopic dermatitis patient, the harmless
S.epidermidis
is sterilized too. This result is not desirable, because the
S.epidermidis
on the skin prevents pathogenic microorganisms from fixing on to and invading the skin. Furthermore, because the distribution of bacteria on the skin becomes unnaturally skewed, the balance of the distribution of bacteria on the skin is disturbed all the more. These have negative effects on atopic dermatitis. For that reason, the conventional antibacterial treatment may not prove effective. Also, the numbers of harmless
S.epidermidis
decrease due to repetition of the conventional treatment. Accordingly, conventional antibacterial treatments for atopic dermatitis tend to gradually allow other harmful bacteria to easily fix on the skin and invade the skin.
SUMMARY OF THE INVENTION
The present invention is achieved in view of the foregoing prior art. An object of the present invention is to provide a selective antibacterial composition which distinguishes the harmful
Staphylococcus aureus
that exists on the skin of a cutaneous disease patient from the harmless
Staphylococcus epidermidis
that exists on healthy skin, which does not affect the growth and development of the harmless
S.epidermidis,
and which effectively treats and prevents cutaneous diseases, especially atopic dermatitis, by limiting its antibacterial action to only the harmful
S.aureus.
The harmful
S.aureus
and the harmless
S.epidermidis
in the present invention are the bacteria that resembled extremely on the taxonomy. Generally, it is extremely difficult to sterilize one of both, or to inhibit the growth of one of both. However, as a result of diligent study by the inventor, the inventor discovered that the concentration of about 2000 ppm of farnesol inhibits the growth of only the harmful
S.aureus
and does not inhibit the growth of the harmless
S.epidermidis.
Furthermore, as a result of diligent study by the inventor, the inventor discovered that xylitol serves as a nutrient for only the harmless
S.epidermidis
and does not serve as the nutrient for the harmful
S.aureus.
Accordingly, the present invention was accomplished.
Namely, a selective antibacterial composition of the present invention contains a farnesol and/or a xylitol.
Also, in the present invention, it is preferable that the selective antibacterial composition contains 0.001 to 10 wt % of the farnesol.
Also, in the present invention, it is preferable that the selective antibacterial composition contains 0.01 to 30 wt % of the xylitol.
Also, in the present invention, it is preferable that the selective antibacterial composition is an external preparation for application to the skin.
Also, in the present invention, it is preferable that the selective antibacterial composition is an external preparation for the treatment of atopic dermatitis.
REFERENCES:
patent: 4220665 (1980-09-01), Klein
patent: 5895643 (1999-04-01), Hoppe et al.
patent: 6136298 (2000-10-01), Gaffar et al.
patent: 0 126/944 A (1984-12-01), None
patent: 0 297/310 A (1989-01-01), None
patent: 0 577/356 A (1994-01-01), None
patent: 2 713/086 (1995-06-01), None
patent: XP 002148392 (1998-01-01), None
patent: 405221823 A (1993-08-01), None
patent: 06305962 (1994-01-01), None
patent: 07188046 A (1995-07-01), None
patent: WO 95/15149 (1995-06-01), None
patent: WO 98/00168 (1998-01-01), None
Vaamonde, G., et al.; Inhibition of Staphylococcus-Aureus C-243 Growth in Laboratory Media with Water Activity adjusted using Less Usual Solutes; 1986 (Recd 1987); pp. 403-404, p. 404, right-hand column; figure 2.
Chao Fei-Fei
Dodson Shelley A.
George Konata M.
Shiseido Co. Ltd.
Venable, Baetjer, Howard & Civiletti
LandOfFree
Selective antibacterial composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective antibacterial composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective antibacterial composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2599547